Prevalence of Amyloidosis in Trauma Patients

Launched by CONSORCI SANITARI DE L'ALT PENEDÈS I GARRAF · Jul 25, 2024

Keywords

ClinConnect Summary

This clinical trial is looking to find out how common a condition called amyloidosis is among patients who are about to have surgery for trauma, which includes injuries from accidents. Amyloidosis is a disease where an abnormal protein builds up in the body’s organs and tissues, which can cause various health problems. The study is currently recruiting participants, and anyone who is on the waiting list for trauma surgery may be eligible if they meet certain criteria. For example, people over 65 years old, those with a family history of amyloidosis, or individuals with specific heart or nerve issues may be included.

If you or a loved one is considering participating, you would need to sign an informed consent form, allowing you to be part of the study. Participants will undergo evaluations to check for signs of amyloidosis but will not be included if they have already been diagnosed with the condition. This study is important because understanding how common amyloidosis is in trauma patients can help improve future care and treatment for those affected.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Men and women included in the waiting list for scheduled trauma surgery with at least one of the following criteria defined as red flags: Over 65 years old; Possible family history of amyloidosis, Cardiac pathology: aortic stenosis, presence of left ventricular hypertrophy defined as interventricular septal thickness \> 12mm measured by echocardiography, history of previous brady- or tachyarrhythmias including cardiac conduction blocks, history of syncope or presyncope, pro BNP \> 300 in previous blood tests; History of sensory peripheral neuropathy; History of nephropathy without etiological diagnosis; History of liver disease without a clear cause.
• • Ability to cooperate in the necessary evaluations.
• • Signed informed consent for inclusion in the study, either by the participant or their legal representative.
• Exclusion Criteria:
• • - Participants previously diagnosed with amyloidosis cannot be included in the study.